Reduction of acute renal allograft rejection by Daclizumab

Transplantation

Volumn 67, Issue 1, 1999, Pages 110-115

  Nashan, Björn ^a   Light, Susan ^b   Hardie, Ian R ^c   Lin, Amy ^b   Johnson, J Robert ^d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HOFFMANN LA ROCHE INC   (United States)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOBLAST ANTIBODY; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID; OKT 3; PLACEBO; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ALPHA CHAIN; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT FAILURE; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033556545     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199901150-00019     Document Type: Article

References (36)

1. Dunn J, Golden D, Van Buren CT, Lewis RM, Lawen J, Kahan BD. Causes of graft loss beyond two years in the cyclosporine era. Transplantation 1992; 49: 349.
2. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752.
3. Tesi RJ, Henry ML, Elkammas EA, Ferguson RM. Predictors of long-term primary cadaveric renal transplant survival. Clin Transplant 1993; 7: 345.
4. Thiel G, Bock A, Spondin M. et al. Long term benefits and risk of cyclosporine A (Sandimmun): an analysis at 10 years. Transplant Proc 1994; 26: 2493.
5. Ferguson R. Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant 1994; 8: 328.
6. Matas A. Chronic rejection in renal transplant recipients: risk factors and correlates. Clin Transplant 1994; 8: 332.
7. Nicol D, MacDonald AS, Lawen J, Belitsky P. Early prediction of renal allograft loss beyond one year. Transplant Int 1996; 6: 153.
8. Harihan S, Alexander JW, Schroeder TJ, First MR. Impact of first acute rejection episode and severity of rejection on cadaveric renal allograft survival. Clin Transplant 1996; 10: 538.
9. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55: 993.
10. Bock HA, Gallati H, Züricher RM, et al. A randomized prospective trial of prophylactic immunosuppression with ATG-Fresenius versus OKT3 after renal transplantation. Transplantation 1995; 59: 830.
11. Abouna GM, Al-Abdullah ICH, Kelly-Sullivan DK, et al. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring. Transplantation 1995; 59: 1564.
12. Mayer DA, Dmitrewski J, Squifflet J-P, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997; 64: 436.
13. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321.
14. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
15. Sollinger HW, for the US Renal Transplantation Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
16. Soulillou JP. Relevant targets for therapy with monoclonal antibodies in allograft transplantation. Kidney Int 1994; 46: 540.
17. Robb RJ, Greene WC, Rusk CM. Low and high affinity cellular receptors for interleukin-2: implications for the level of Tac antigen. J Exp Med 1984; 160: 1126.
18. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (VD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60: 748.
19. Nashan B, Moore R, Amlot P, Schmidt A-G, Abeywickrama K, Soulillou J-P. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193.
20. Vincenti F, Lantz M, Birnbaum J, et al. A phase I trial of humanized anti-interleukin-2 receptor antibody in renal transplantation. Transplantation 1997; 63: 33.
21. Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac, an antibody that binds to the interleukin-2 receptor. Blood 1994; 84: 1320.
22. Brown PS, Parenteau GL, Dirbas FM, et al. Anti-Tac-H, a humanized antibody to the interleukin-2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA 1991; 88: 2663.
23. Cosimi AB, Colvin RB, Burton RC, et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981; 305: 308.
24. Thistlethwaite JR, Cosimi AB, Delmonico FL, et al. Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection. Transplantation 1984; 38: 695.
25. Ortho Multicenter Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337.
26. Goldstein G, Norman D, Pharmacokinetic study of Orthoclone OKT3 serum levels during treatment of acute renal allograft rejection. Transplantation 1988; 45: 587.
27. Hakimi J, Chizzonite R, Luke DR, et al. Reduced immunogenicity and improved pharmocokinetics of humanized anti-Tac in cynomolgus monkeys. J Immunol 1991; 147: 1352.
28. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin-2 receptor. Proc Natl Acad Sci USA 1989; 86: 10029.
29. Junghans RP, Waldmann TA, Landolfi NF, Avdalovi NM, Schneider WP, Queen C. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 1990; 50: 1495.
30. Cockfield SM, Preiksaitis JK, Jewell LD, Paffrey NA. Post-transplant lymphoproliferative disorder in renal allograft recipients. Transplantation 1993; 56: 88.
31. Nalesnik MA, Lymphoproliferative disease in organ transplant recipients. Springer Semin Immunopathol 1991; 13: 199.
32. Kirkman RL, Shapiro ME, Carpenter DB, et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 1991; 51: 107.
33. Soulillou JP, Cantorovich D, LeMauff B, et al. Randomized controlled trial of monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 332: 1175.
34. van Gelder T, Zietse R, Mulder AH, et al. A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation. Transplantation 1995; 60: 248.
35. Nashan B, Schlitt HJ, Schwinzer R, et al. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients. Transplantation 1996; 61: 546.
36. Nashan B, Schwinzer R, Schlitt HJ, Wonigeit K, Pichlmayr R. Immunologic effect of the anti-IL-2 receptor monoclonal antibody BT563 in liver allografted patients. Transplant Immunol 1995; 3: 203.